Amplius Wealth Advisors LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jul 12th, 2023

Amplius Wealth Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,721 shares of the biopharmaceutical company’s stock after buying an additional 1,532 shares during the quarter. Amplius Wealth Advisors LLC’s holdings in Pfizer were worth $1,457,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Harbor Investment Advisory LLC boosted its stake in shares of Pfizer by 3.6% during the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 825 shares during the period. BancFirst Trust & Investment Management lifted its stake in Pfizer by 2.3% in the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 398 shares during the period. Secure Asset Management LLC lifted its stake in Pfizer by 3.5% in the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after acquiring an additional 537 shares during the period. Center For Asset Management LLC lifted its stake in Pfizer by 28.0% in the first quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock worth $975,000 after acquiring an additional 5,228 shares during the period. Finally, Range Financial Group LLC lifted its stake in Pfizer by 2.8% in the first quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock worth $1,510,000 after acquiring an additional 1,024 shares during the period. 67.80% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE opened at $36.01 on Wednesday. Pfizer Inc. has a 52-week low of $35.35 and a 52-week high of $54.93. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a market cap of $203.29 billion, a P/E ratio of 7.09, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The firm’s 50-day moving average price is $37.90 and its 200-day moving average price is $41.28.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. The firm had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. Pfizer’s revenue for the quarter was down 28.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.62 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Friday, July 28th will be given a $0.41 dividend. The ex-dividend date is Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a yield of 4.55%. Pfizer’s dividend payout ratio is currently 32.28%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction that occurred on Friday, May 5th. The shares were purchased at an average price of $38.42 per share, for a total transaction of $38,420.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $192,100. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Bank of America lowered their price objective on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a research note on Friday, April 21st. StockNews.com downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 30th. Morgan Stanley reduced their target price on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating for the company in a report on Monday, April 10th. UBS Group reduced their target price on shares of Pfizer from $41.00 to $39.00 in a report on Friday, May 5th. Finally, Credit Suisse Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $47.00 to $40.00 in a report on Thursday, June 29th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $46.53.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.